ARTICLE | Clinical News
TKTX long-term Replagal data
October 16, 2001 7:00 AM UTC
Transkaryotic Therapies (TKTX) said data from a 12-month open-label extension of its 6-month pivotal Phase II trial showed that Fabry disease patients crossing over to Replagal agalsidase alfa enzyme ...